Literature DB >> 22869477

Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience.

Tak Geun Oh1, Moon Jae Chung, Jeong Yeop Park, Seung Min Bang, Seung Woo Park, Jae Bok Chung, Si Young Song.   

Abstract

PURPOSE: Pancreatic neuroendocrine tumors (PNET) are a rare subgroup of tumors. For PNETs, the predictive factors for survival and prognosis are not well known. The purpose of our study was to evaluate the predictive factors for survival and disease progression in PNETs.
MATERIALS AND METHODS: We retrospectively analyzed 37 patients who were diagnosed with PNET at Severance Hospital between November 2005 and March 2010. Prognostic factors for survival and disease progression were evaluated using the Kaplan-Meier method.
RESULTS: The mean age of the patients was 50.0±15.0 years. Eight cases (21.6%) were described as functioning tumors and 29 cases (78.4%) as non-functioning tumors. In univariate analysis of clinical factors, patients with liver metastasis (p=0.002), without resection of primary tumors (p=0.002), or American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) stage III/IV (p=0.002) were more likely to demonstrate shorter overall survival (OS). Patients with bile duct or pancreatic duct invasion (p=0.031), sized-lesions larger than 20 mm (p=0.036), liver metastasis (p=0.020), distant metastasis (p=0.005), lymph node metastasis (p=0.009) or without resection of primary tumors (p=0.020) were more likely to demonstrate shorter progression-free survival (PFS). In multivariate analysis of clinical factors, bile duct or pancreatic duct invasion [p=0.010, hazard ratio (HR)=95.046] and tumor location (non-head of pancreas) (p=0.036, HR=7.381) were confirmed as independent factors for predicting shorter PFS.
CONCLUSION: Patients with liver metastasis or without resection of primary tumors were more likely to demonstrate shorter OS. Patients with bile duct or pancreatic duct invasion or tumors located at body or tail of pancreas were more likely to demonstrate shorter PFS.

Entities:  

Mesh:

Year:  2012        PMID: 22869477      PMCID: PMC3423842          DOI: 10.3349/ymj.2012.53.5.944

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  22 in total

1.  Neuroendocrine tumours of the pancreas.

Authors:  B Eriksson; K Oberg
Journal:  Br J Surg       Date:  2000-02       Impact factor: 6.939

2.  Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.

Authors:  F R Nobels; D J Kwekkeboom; W Coopmans; C H Schoenmakers; J Lindemans; W W De Herder; E P Krenning; R Bouillon; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

3.  Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Authors:  Francesco Panzuto; Silvia Nasoni; Massimo Falconi; Vito Domenico Corleto; Gabriele Capurso; Sara Cassetta; Michela Di Fonzo; Valentina Tornatore; Massimo Milione; Stefano Angeletti; Maria Sofia Cattaruzza; Vincenzo Ziparo; Cesare Bordi; Paolo Pederzoli; Gianfranco Delle Fave
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

Review 4.  Endocrine tumours of the pancreas.

Authors:  Kjell Oberg; Barbro Eriksson
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-10       Impact factor: 3.043

5.  [Clinical features of neuroendocrine tumor of the pancreas: single center study].

Authors:  Tae Wook Kang; Kyu Taek Lee; Min Kyu Ryu; Won Moon; Sang Soo Lee; Sun-Young Lee; Ji Young Hwang; Jong Kyun Lee; Jin Seok Heo; Seong Heum Choi; Sang Heum Kim; Seung Woon Paik; Jong Chul Rhee
Journal:  Korean J Gastroenterol       Date:  2006-08

6.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

7.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.

Authors:  Ulrich-Frank Pape; Henning Jann; Jacqueline Müller-Nordhorn; Angelina Bockelbrink; Uta Berndt; Stefan N Willich; Martin Koch; Christoph Röcken; Guido Rindi; Bertram Wiedenmann
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

8.  Diagnosis and surgical treatment of pancreatic endocrine tumors in 36 patients: a single-center report.

Authors:  Hong Liu; Su-zhan Zhang; Yu-lian Wu; He-qing Fang; Jiang-tao Li; Hong-wei Sheng; Yong Wang
Journal:  Chin Med J (Engl)       Date:  2007-09-05       Impact factor: 2.628

9.  Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?

Authors:  H Chen; J M Hardacre; A Uzar; J L Cameron; M A Choti
Journal:  J Am Coll Surg       Date:  1998-07       Impact factor: 6.113

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  4 in total

Review 1.  Practical management and treatment of pancreatic neuroendocrine tumors.

Authors:  Naoko Iwahashi Kondo; Yasuharu Ikeda
Journal:  Gland Surg       Date:  2014-11

2.  Outcomes and prognostic factors of patients with stage IB and IIA pancreatic cancer according to the 8th edition American Joint Committee on Cancer criteria.

Authors:  Yang Li; Chuan-Gang Tang; Yu Zhao; Wu-You Cao; Guo-Feng Qu
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

Review 3.  Usefulness of partial splenic embolization for left-sided portal hypertension in a patient with a pancreatic neuroendocrine neoplasm: a case report and review of the literature.

Authors:  Teppei Matsui; Hidenari Nagai; Makoto Amanuma; Kojiro Kobayashi; Yu Ogino; Takanori Mukozu; Noritaka Wakui; Naoki Okano; Yoshinori Kikuchi; Takahisa Matsuda; Yoshinori Igarashi
Journal:  Clin J Gastroenterol       Date:  2022-04-16

4.  Biliary Neuroendocrine Neoplasms: Analysis of Prognostic Factors and Development and Validation of a Nomogram.

Authors:  Shengnan Zhou; Shitao Jiang; Weijie Chen; Haixin Yin; Liangbo Dong; Hao Zhao; Shaoqi Han; Xiaodong He
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.